{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:10:59Z","timestamp":1789186259169,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijantimicag.2026.107723","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:22:47Z","timestamp":1769732567000},"page":"107723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Resistance of uropathogens to gepotidacin: A systematic review of in vitro antimicrobial susceptibility studies"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8068-8575","authenticated-orcid":false,"given":"Matthew E.","family":"Falagas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura T.","family":"Romanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni D.","family":"Katritsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1206-6202","authenticated-orcid":false,"given":"Iva D.","family":"Tzvetanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107723_bib0001","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/s41598-025-89240-5","article-title":"Epidemiological trends and predictions of urinary tract infections in the Global Burden of Disease Study 2021","volume":"15","author":"He","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0002","first-page":"373","article-title":"The diagnosis, treatment, and prevention of recurrent urinary tract infection","volume":"121","author":"Schmiemann","year":"2024","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0003","first-page":"40","article-title":"Urinary tract infection in women","volume":"20","author":"Czajkowski","year":"2021","journal-title":"Prz Menopauzalny"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0004","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jinf.2008.12.009","article-title":"Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized controlled trials","volume":"58","author":"Falagas","year":"2009","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/antibiotics12010183","article-title":"Fluoroquinolones are useful as directed treatment for complicated UTI in a setting with a high prevalence of quinolone-resistant microorganisms","volume":"12","author":"Artero","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0006","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s10096-013-1891-z","article-title":"Antimicrobial activity of prulifloxacin in comparison with other fluoroquinolones against community-acquired urinary and respiratory pathogens isolated in Greece","volume":"32","author":"Karageorgopoulos","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0007","first-page":"249","article-title":"Optimal macroculture method for studying mitogenic stimulation of turkey lymphocytes","volume":"42","author":"Tessler","year":"1978","journal-title":"Can J Comp Med"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0008","first-page":"CR75","article-title":"Antimicrobial resistance of Esherichia coli urinary isolates from primary care patients in Greece","volume":"14","author":"Falagas","year":"2008","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0009","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1089\/mdr.2016.0318","article-title":"Frequency and antibiotic resistance of bacteria implicated in community urinary tract infections in North Aveiro between 2011 and 2014","volume":"24","author":"Costa","year":"2018","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10096-016-2776-8","article-title":"Uropathogen distribution and antimicrobial susceptibility in uncomplicated cystitis in Belgium, a high antibiotics prescribing country: 20-year surveillance","volume":"36","author":"Heytens","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0011","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s11255-010-9768-x","article-title":"Antimicrobial susceptibility of pediatric uropathogens in Thrace, Greece","volume":"43","author":"Mantadakis","year":"2011","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0012","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2490-12-33","article-title":"Resistance profiles of urinary tract infections in general practice-an observational study","volume":"12","author":"Schmiemann","year":"2012","journal-title":"BMC Urol"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0013","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/10600280251343682","article-title":"Gepotidacin: a novel antibiotic for the treatment of uncomplicated urinary tract infections","volume":"60","author":"Durham","year":"2026","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0014","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","article-title":"Mechanistic and structural basis for the actions of the antibacterial gepotidacin against Staphylococcus aureus gyrase","volume":"5","author":"Gibson","year":"2019","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0015","doi-asserted-by":"crossref","first-page":"e00207","DOI":"10.1128\/AAC.00207-19","article-title":"Rapid evolution of reduced susceptibility against a balanced dual-targeting antibiotic through stepping-stone mutations","volume":"63","author":"Szili","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0016","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/jac\/dkad060","article-title":"Gepotidacin: a novel, oral, \u2018first-in-class\u2019 triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea","volume":"78","author":"Watkins","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0017","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1021\/acsinfecdis.5c00497","article-title":"Mechanism of action of gepotidacin: well-balanced dual-targeting against Neisseria gonorrhoeae gyrase and topoisomerase IV in cells and in vitro","volume":"11","author":"Oviatt","year":"2025","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0018","series-title":"BLUJEPA (gepotidacin) tablets, for oral use: prescribing information","year":"2018"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0019","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00521-20","article-title":"Relationship between gepotidacin exposure and prevention of on-therapy resistance amplification in a Neisseria gonorrhoeae hollow-fiber in vitro infection model","volume":"64","author":"VanScoy","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0020","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1128\/AAC.00625-15","article-title":"Pharmacodynamic profile of GSK2140944 against methicillin-resistant Staphylococcus aureus in a murine lung infection model","volume":"59","author":"So","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0021","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02165-21","article-title":"In vitro activity of gepotidacin against Gram-negative and Gram-positive anaerobes","volume":"66","author":"Hackel","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0022","article-title":"P-1062. In vitro activity of gepotidacin and comparator agents against a collection of K. pneumoniae urine isolates from the united states during 2019-2022","volume":"12","author":"Arends","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0023","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00296-25","article-title":"In vitro activity of gepotidacin against urinary tract infection isolates of Enterobacterales, Enterococcus faecalis, and Staphylococcus saprophyticus","volume":"69","author":"Hackel","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0024","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.1248","article-title":"P-1059. In vitro activity of gepotidacin against Klebsiella pneumoniae, including molecularly characterized ESBL and carbapenemase positive subsets causing urinary tract infections in the United States (2019-2022)","volume":"12","author":"Mendes","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0025","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.1249","article-title":"P-1060. In vitro activity of gepotidacin tested against molecularly characterized Escherichia coli isolates responsible for urinary tract infections in the US (2019-2022)","volume":"12","author":"Mendes","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0026","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.1250","article-title":"P-1061. In vitro activity of gepotidacin against Klebsiella pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in the United States (2019-2022)","volume":"12","author":"Mendes","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0027","article-title":"Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3)","volume":"69","author":"Scangarella-Oman","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0028","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad500.1782","article-title":"2159. Analysis of resistance to oral standard-of-care antibiotics for urinary tract infections caused by Escherichia coli and Staphylococcus saprophyticus collected in the united states in 2022","volume":"10","author":"Arends","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0029","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01525-22","article-title":"Antimicrobial activity of gepotidacin tested against Escherichia coli and staphylococcus saprophyticus isolates causing urinary tract infections in medical centers worldwide (2019 to 2020)","volume":"67","author":"Arends","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2023.115946","article-title":"Analysis of the effect of urine on the in vitro activity of gepotidacin and levofloxacin against Escherichia coli, Staphylococcus epidermidis, and Staphylococcus saprophyticus","volume":"106","author":"Koeth","year":"2023","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0031","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac492.1305","article-title":"1675. Activity of gepotidacin against Escherichia coli isolates from community-acquired urinary tract infections collected between 2019 and 2021 in the United States","volume":"9","author":"Arends","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128648","article-title":"Discovery and structure\u2013activity relationships of a novel oxazolidinone class of bacterial type II topoisomerase inhibitors","volume":"65","author":"Lyons","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0033","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac492.693","article-title":"641. Activity of gepotidacin tested against molecularly characterized Escherichia coli isolates resistant to commonly used oral therapies for UTI in the US (2019-2020)","volume":"9","author":"Mendes","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0034","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/antibiotics11020192","article-title":"Antibacterial activity of the novel drug gepotidacin against Stenotrophomonas maltophilia\u2014an in vitro and in vivo study","volume":"11","author":"Sanders","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0035","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00468-17","article-title":"Gepotidacin (GSK2140944) in vitro activity against Gram-positive and Gram-negative bacteria","volume":"61","author":"Flamm","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0036","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/AAC.02820-15","article-title":"In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens","volume":"60","author":"Biedenbach","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0037","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/acsinfecdis.3c00346","article-title":"Interactions between gepotidacin and Escherichia coli gyrase and topoisomerase IV: genetic and biochemical evidence for well-balanced dual-targeting","volume":"10","author":"Oviatt","year":"2024","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0038","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00122-21","article-title":"Gepotidacin pharmacokinetics-pharmacodynamics against Escherichia coli in the one-compartment and hollow-fiber in vitro infection model systems","volume":"65","author":"VanScoy","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107723_bib0043","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","article-title":"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials","volume":"403","author":"Wagenlehner","year":"2024","journal-title":"The Lancet"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926000129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926000129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:08:52Z","timestamp":1773317332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926000129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0924857926000129"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107723","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance of uropathogens to gepotidacin: A systematic review of in vitro antimicrobial susceptibility studies","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107723"}}